Skip to main content Skip to main content
Go to homepage
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Oxybutynin for Neurogenic Bladder

Safety and effectiveness of oxybutynin in children (6-16 years) with neurogenic bladder

Who May Qualify?:

Patients 6-16 years old with neurogenic detrusor overactivity

Who Does Not Qualify:

Patients who are pregnant, involved in other investigational studies or have certain medical conditions

Study Status:
Closed
Full IRB Study Title:
A Multi-Center, Double-Blind, Placebo-Controlled, Dose-Titration Study Evaluating the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride Topical Gel for the Treatment of Detrusor Overactivity Associated with a Neurological Condition in Pediatric Subjects
IRB Study ID:
110208
If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

Lead Investigator
Daniel McMahon, MD

Director, Pediatric Urology; Pediatric Urologist
Pediatric UrologyKidney Stone Clinic

Starting Locations:
Career Opportunities
Legal:
Mobile App:

Akron Children's Anywhere:

About Akron Children's

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...

Akron Children's
One Perkins Square, Akron, Ohio 44308-1062
330-543-1000 • webmaster@akronchildrens.org
An Equal Opportunity Employer
Copyright © 2020, Akron Children's. All Rights Reserved.
  • Magnet Recongnition
  • Newsweek: World's Best Hospitals - 2023
  • Newsweek: World's Best Hospitals - Pediatrics 2023

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.